StockData
TEVANYSEPharmaceutical PreparationsFiscal year ends December 31

TEVA PHARMACEUTICAL INDUSTRIES LTD

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026

Market cap
$48.13B
P/E (TTM)
68.9
Dividend yield
–

Earnings

Next report expected Nov 4, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 29, 2026Before market open$4.14B$-0.49$0.02
Q1 FY2026
Ended Mar 31, 2026
Apr 29, 2026Before market open$3.98B$0.31$0.53
Q4 FY2025
Ended Dec 31, 2025
Jan 12, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 5, 2025Before market open$4.50B$0.37$0.78
Q2 FY2025
Ended Jun 30, 2025
Jul 30, 2025Before market open$4.18B$0.24$0.66
Q1 FY2025
Ended Mar 31, 2025
May 7, 2025Before market open$3.90B$0.18$0.52
Q4 FY2024
Ended Dec 31, 2024
Jan 29, 2025Before market open$4.20B$-0.19$0.71
Q3 FY2024
Ended Sep 30, 2024
Nov 6, 2024Before market open$4.33B$-0.39$0.69
Q2 FY2024
Ended Jun 30, 2024
Jul 31, 2024Before market open$4.16B$-0.75$0.61
Q1 FY2024
Ended Mar 31, 2024
May 8, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Jan 31, 2024Before market open–––

Company guidance

Outlook given with results on Jul 29, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
CAPEX2026$500.00MNew
Adjusted EBITDAnon-GAAP2026$4.23B to $4.53BMaintained
Non-GAAP diluted EPSnon-GAAP2026$1.91 to $2.11Maintained
Free cash flow2026$2.00B to $2.40BNew
Non-GAAP operating incomenon-GAAP2026$3.80B to $4.00BMaintained
annual non-GAAP tax ratenon-GAAP202620% to 23%New
Finance Expenses*2026$800.00MNew
Revenues2026$16.50B to $16.85BRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Teva Pharmaceutical Industries filed with the SEC